---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-004262"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-07T00:03:52.689817+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics CFO Jason Amello resigns; Charles Schoch named interim CFO

## Summary
- Jason A. Amello resigned as CFO effective Jan 12, 2024, to pursue another opportunity.
- Board appointed Charles Schoch as interim CFO, effective Jan 12, 2024.
- Schoch had served as VP of Finance and Corporate Controller since March 2023.
- Schoch's annual base salary increased to $325,000 as interim CFO.
- Schoch is a CPA with prior experience at Corbus Pharmaceuticals and PwC.

## SEC filing metadata
- accession: 0000950170-24-004262
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/cadl-20240112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-004262
- JSON: https://secwatch.observer/filing/0000950170-24-004262.json
- Plain text: https://secwatch.observer/filing/0000950170-24-004262.txt

## Key facts
- Executive change
  Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm
- Executive change
  Charles Schoch was appointed as interim Chief Financial Officer at Candel Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.